What is Tempus AI, Inc. stock?

Tempus AI, Inc. Business Introduction

Tempus AI, Inc. (Nasdaq: TEM) is a technology company leading the convergence of healthcare and artificial intelligence. Founded with the mission to define how genomic and clinical data can enhance patient care, Tempus has developed what it calls the world’s largest library of clinical and molecular data, paired with an operating system that makes this data accessible and actionable for physicians and researchers.

Business Modules in Detail

1. Genomics (Genomic Profiling): This is the primary revenue driver. Tempus offers comprehensive molecular sequencing services (DNA and RNA) to detect genetic alterations in a patient’s tumor. Unlike traditional laboratories, Tempus integrates this genomic data with longitudinal clinical data (treatment history, outcomes) from Electronic Health Records (EHR).
2. Data and Services (Biopharma): Tempus licenses its de-identified, multimodal database to pharmaceutical and biotechnology companies. This data supports drug discovery, clinical trial design, and companion diagnostic development. As of early 2026, Tempus has partnered with nearly all of the top 20 global pharmaceutical companies.
3. AI Applications (Algos): Tempus develops and deploys clinical AI tools, including "Prognostic Tests" that predict patient responses to specific therapies and "Natural Language Processing" tools that extract structured data from unstructured clinical notes. Their "Tempus One" platform serves as a voice-activated assistant enabling oncologists to query patient data in real time.
4. Clinical Trials (Trials): Leveraging its data, Tempus matches patients to clinical trials more efficiently than traditional methods through its "TIME" (Trial Integrated Molecular Evaluation) program, reducing the time needed to activate trial sites and enroll participants.

Commercial Model Characteristics

Tempus operates a Flywheel Model: as more physicians use their genomic tests, the company collects more clinical and molecular data. This data enhances their AI algorithms, which in turn delivers greater value to physicians, driving higher adoption and generating more data.
Revenue is diversified through Product Revenue (clinical testing paid by insurers/patients) and Subscription/Licensing Revenue (data and software access paid by biopharma).

Core Competitive Moat

· Multimodal Data Superiority: Tempus possesses not only genomic sequences but also "linked" data. Their competitive advantage lies in the scale of over 10 petabytes of clinical data connected to molecular profiles, which is extremely difficult for competitors to replicate.
· High Switching Costs: By integrating directly with hospital EHR systems (Epic, Cerner), Tempus becomes an indispensable part of clinical workflows, making it challenging for providers to switch to other testing labs.
· Regulatory & Patent Barrier: The company holds numerous FDA clearances for its AI-driven diagnostic tools, creating a legal and regulatory shield against new entrants.

Latest Strategic Layout

In 2025 and early 2026, Tempus has aggressively expanded into Neuropsychiatry and Cardiology, moving beyond its initial oncology focus. Their recent acquisition strategy targets AI imaging companies to integrate radiology data into their multimodal platform, aiming to provide a comprehensive 360-degree view of patient health.

Tempus AI, Inc. Development History

Tempus AI was founded in 2015 by Eric Lefkofsky (also co-founder of Groupon). The company’s growth trajectory is marked by rapid scaling and a focus on "data-first" healthcare.

Development Phases

Phase 1: Foundation and Oncology Focus (2015 - 2018)
Tempus began by addressing the most data-intensive field: cancer. It spent its early years building partnerships with major academic medical centers to collect clinical data and establishing a high-throughput sequencing lab in Chicago.

Phase 2: Scale and Biopharma Integration (2019 - 2022)
The company transitioned from a "testing lab" to a "data company," signing multi-million dollar agreements with pharmaceutical giants. During this period, it raised billions in private funding from investors such as Google (Alphabet), Baillie Gifford, and Franklin Templeton.

Phase 3: AI Productization and IPO (2023 - 2024)
Tempus launched "Tempus One," leveraging Large Language Models (LLMs) to make their data library conversational. In June 2024, Tempus AI successfully went public on Nasdaq, raising approximately $410 million and valuing the company at over $6 billion at the time of the offering.

Phase 4: Multi-Disease Expansion (2025 - Present)
Post-IPO, the company has deployed its capital to expand into cardiology (AFib prediction) and mental health, aiming to become the "Operating System for Healthcare."

Success Factors and Challenges

Success Factors: The "Lefkofsky Effect" (strong entrepreneurial leadership), early AI adoption, and a unique focus on multimodal data (integrating diverse data types) rather than genomics alone.
Challenges: High R&D expenses and slow insurance reimbursement for advanced genomic testing have historically led to net losses, requiring sustained high growth to achieve profitability.

Industry Introduction

Tempus AI operates within the Precision Medicine and Healthcare AI sectors. This industry is shifting from a "one-size-fits-all" treatment model to personalized care based on an individual’s genetic profile and clinical history.

Industry Trends and Catalysts

1. Explosion of Generative AI: LLMs are increasingly used to synthesize vast medical literature and patient records, a trend pioneered by Tempus with Tempus One.
2. Declining Sequencing Costs: The cost of sequencing a human genome continues to decrease, making genomic profiling a standard of care rather than a luxury.
3. Transition to Value-Based Care: Payers are increasingly rewarding providers who leverage data to improve patient outcomes and reduce unnecessary treatments.

Competitive Landscape

Industry Status and Data

According to market research (e.g., Grand View Research), the global precision medicine market is projected to grow at a CAGR of approximately 11.5% from 2024 to 2030.
In its Q3 2025 earnings report, Tempus AI reported year-over-year revenue growth exceeding 25%, driven largely by its AI-assisted data services and expanded clinical testing volume. By the end of 2025, Tempus’s network included over 2,000 healthcare institutions and 65% of all Academic Medical Centers in the United States, solidifying its position as a dominant platform player in the American healthcare data landscape.

Tempus AI, Inc. Financial Health Rating

Tempus AI has demonstrated a significant pivot from a high-burn startup to a company achieving operational scale. While its top-line growth is exceptional, its GAAP-level profitability remains weighed down by stock-based compensation and debt-to-equity ratios.

Tempus AI, Inc. Development Potential

1. Explosive Growth in High-Margin Segments

The company’s **Data and Applications** segment (Insights) is becoming a massive profit engine. In Q4 2025, this segment's organic growth hit **69.5%** with gross margins exceeding **74%**. As Tempus transitions from a lab-heavy business to a data-licensing powerhouse, its overall corporate margins are expected to expand significantly.

2. The "Beachfront Property" Strategy (AI Moat)

CEO Eric Lefkofsky describes their data library (over 45 million patient records) as "farmland becoming beachfront property." By launching **Paige Predict** and other AI-powered tools, Tempus is monetizing its data via software checkboxes that predict biomarkers directly from digital pathology slides. This represents "pure profit" potential with minimal incremental costs.

3. Clinical Catalysts: MRD Testing Expansion

Minimal Residual Disease (MRD) testing is the next major frontier. Volume grew **56% quarter-over-quarter** in late 2025 despite limited sales force engagement. Management plans to submit **tumor-naive assays** for lung and colorectal cancer for reimbursement in 2026, which could unlock a 20x volume increase if rolled out to the full sales force.

4. Strategic Partnerships and Acquisitions

The **$200M collaboration with AstraZeneca** and the acquisition of **Ambry Genetics** and **Paige.ai** have fortified Tempus’s position as a multimodal AI leader. These moves provide the "fuel" (data) for their foundation models, creating a network effect that competitors find difficult to replicate.

Tempus AI, Inc. Company Benefits & Risks

Company Benefits (Upside Catalysts)

• First-Mover Advantage: Holds one of the world's largest libraries of clinical and molecular oncology data.
• Net Revenue Retention (NRR): A high NRR of 126% to 140% indicates that existing pharma clients are spending more each year, demonstrating high "stickiness."
• Operational Pivot: Successfully reached positive Adjusted EBITDA in late 2025, proving the business model can scale toward profitability.
• AI Infrastructure Tailwinds: As healthcare shifts toward precision medicine, Tempus is positioned as the primary data infrastructure provider for drug discovery.

Company Risks (Downside Factors)

• GAAP Net Losses: Despite operational success, persistent GAAP losses (e.g., $245M in FY2025) due to high stock-based compensation may deter conservative investors.
• High Volatility: The stock has a high beta (approx. 5), making it sensitive to macro shifts and sentiment changes in the AI sector.
• Guidance Scrutiny: The 2026 revenue guidance of $1.59B implies a growth normalization to ~25%, which some aggressive growth investors may view as "muted" compared to the 80%+ seen in 2025.
• Concentration of Control: The CEO holds a supervoting majority, meaning public shareholders have limited influence over major corporate decisions.

How do Analysts View Tempus AI, Inc. and TEM Stock?

Following its high-profile IPO in mid-2024, Tempus AI, Inc. (TEM) has attracted significant attention from Wall Street. Analysts generally regard the company as a pioneer at the crossroads of "Big Data" and healthcare, particularly within the rapidly expanding field of precision medicine. As of early 2026, the consensus reflects a "high-growth, high-conviction" outlook, tempered by concerns regarding the path to profitability and valuation volatility.

1. Core Institutional Perspectives on the Company

The "Data Moat" Strategy: Leading analysts from firms such as J.P. Morgan and Morgan Stanley emphasize that Tempus AI’s primary value lies in its proprietary de-identified clinical and molecular dataset, one of the largest globally. Analysts believe this data repository creates a significant competitive advantage (a "moat") that gains value as more genomic data fragments and clinical records are incorporated.

AI-Driven Healthcare Integration: Stifel and TD Cowen highlight Tempus's unique capability to embed AI into physicians’ workflows via its "Tempus One" platform. Analysts see the company not merely as a diagnostics lab but as a technology infrastructure provider for oncology and beyond, including cardiology and neuropsychiatry.

Pharma Partnerships: A key bullish argument centers on the company’s Data and Services segment. Analysts track collaborations with major pharmaceutical firms (such as AstraZeneca and GSK) as a recurring, high-margin revenue source that sets Tempus apart from traditional diagnostic peers.

2. Stock Ratings and Price Targets

As of the latest quarterly reports in late 2025 and early 2026, market sentiment toward TEM remains largely positive:

Rating Distribution: Among approximately 15 leading analysts covering the stock, over 80% maintain a "Buy" or "Overweight" rating. There are currently no major "Sell" ratings, though a few "Hold" ratings persist due to valuation concerns.

Price Target Forecasts:
Average Target Price: Analysts have set a consensus target range of $72.00 to $78.00, indicating significant upside from late-2025 trading levels.
Bull Case: Top-tier analysts at Needham have issued aggressive targets up to $85.00, citing faster-than-expected adoption of the "Pathology" and "Liquid Biopsy" product lines.
Bear Case: More conservative estimates from Bank of America hover around $55.00, reflecting caution regarding the timing of the company’s transition to positive Free Cash Flow (FCF).

3. Analyst-Identified Risk Factors (The Bear Case)

Despite technological optimism, analysts caution investors about several critical risks:

Path to Profitability: While revenue growth has been robust (exceeding 25-30% year-over-year in recent quarters), Tempus continues to report net losses. Analysts at Goldman Sachs note that the company’s heavy R&D expenditure and high cost of revenue for genomic testing could delay GAAP profitability until 2027 or later.

Regulatory and Reimbursement Uncertainty: As with any medical technology company, Tempus is subject to FDA oversight and changes in Medicare/Medicaid reimbursement rates. Analysts warn that any downward revision in reimbursement for NGS (Next-Generation Sequencing) tests could impact margins.

Concentration Risk: A significant portion of revenue depends on a limited number of biopharma contracts. Analysts closely monitor these "lumpy" revenue cycles, as losing a major partner could lead to quarterly earnings shortfalls.

Summary

The Wall Street consensus on Tempus AI is that it represents a "Category-Defining" investment in the AI-healthcare sector. Analysts view the stock as a high-beta play on the future of personalized medicine. While the stock is subject to volatility influenced by interest rate environments and quarterly cash burn, most analysts believe Tempus AI’s expanding database and its application in drug discovery make it a foundational holding for investors seeking exposure to the Genomic Revolution 2.0.

Tempus AI, Inc. (TEM) Frequently Asked Questions

What are the key investment highlights for Tempus AI, and who are its main competitors?

Tempus AI (TEM) is a leader in the convergence of healthcare and artificial intelligence, specializing in precision medicine. Its primary investment highlights include its vast proprietary database of clinical and molecular data, which powers its AI-driven diagnostic tests. The company operates a "flywheel" model where more data leads to better insights, attracting more biopharma partners.
Key competitors include Guardant Health (GH), Foundation Medicine (owned by Roche), and Exact Sciences (EXAS). Tempus differentiates itself by integrating laboratory testing with an advanced AI platform (the "Intelligent OS") used by over 2,000 healthcare institutions and many of the world's leading pharmaceutical companies.

Are Tempus AI’s latest financial metrics healthy? How are its revenue, net income, and debt?

Based on the latest financial reports for Q3 2024, Tempus AI reported robust revenue growth. Quarterly revenue reached $180.9 million, a 33% year-over-year increase. However, like many high-growth AI biotech firms, the company is still in its scaling phase and reported a net loss of $74.8 million for the quarter, though this marked a significant improvement compared to the prior year.
As of September 30, 2024, the company maintained a strong liquidity position with approximately $447 million in cash and cash equivalents. While the company carries debt related to its operational scaling, its successful IPO in June 2024 significantly strengthened its balance sheet to support future R&D.

Is the current TEM stock valuation high? How do its P/S and P/B ratios compare to the industry?

Since Tempus AI is currently unprofitable, traditional Price-to-Earnings (P/E) ratios are not applicable. Investors typically focus on the Price-to-Sales (P/S) ratio. As of late 2024, TEM trades at a P/S ratio of approximately 10x to 12x, which is higher than the average for the broader healthcare sector but remains competitive within the high-growth AI-biotech and diagnostics industry.
Compared to peers like Guardant Health, Tempus often commands a premium due to its extensive data library and AI software capabilities, which investors view as a high-margin recurring revenue opportunity over the long term.

How has TEM stock performed over the past few months compared to its peers?

Since its IPO in June 2024 at $37.00 per share, TEM has experienced significant volatility. In the past three months, the stock has shown strong upward momentum, often outperforming the S&P 500 Healthcare Index and peers like Illumina (ILMN). This performance was largely driven by positive earnings surprises and new partnership announcements with major pharmaceutical firms. However, like many growth stocks, it remains sensitive to interest rate fluctuations and broader tech sector sentiment.

Are there any recent industry tailwinds or headwinds affecting Tempus AI?

Tailwinds: The rapid adoption of Generative AI in healthcare is a major tailwind. Recent FDA clearances for AI-assisted diagnostic tools and the shift toward personalized oncology treatments favor Tempus AI’s business model. Additionally, the increasing demand from big pharma for "Real-World Data" (RWD) to accelerate drug discovery is a significant growth driver.
Headwinds: Potential risks include changes in Medicare reimbursement rates for genomic testing and intense competition in the liquid biopsy market. Regulatory scrutiny over how AI models are validated in clinical settings also remains a factor to monitor.

Have major institutional investors been buying or selling TEM stock recently?

Institutional interest in Tempus AI is high. Notable backers include SoftBank, a significant long-term investor. Following the IPO, several major asset managers such as Vanguard Group and BlackRock have established positions in the company as it was added to various growth indices. According to recent 13F filings, institutional ownership remains a key support level for the stock, reflecting confidence in the company’s "AI + Data" long-term strategy.